Financials data is unavailable for this security.
View more
Year on year Arbutus Biopharma Corp 's revenues fell -53.51% from 39.02m to 18.14m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 69.46m to a larger loss of 72.85m.
| Gross margin | -- |
|---|---|
| Net profit margin | -1,137.65% |
| Operating margin | -1,233.06% |
| Return on assets | -51.29% |
|---|---|
| Return on equity | -67.81% |
| Return on investment | -59.50% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Arbutus Biopharma Corp fell by 4.49m. However, Cash Flow from Investing totalled 50.77m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 85.94m for operations while cash generated from financing totalled 30.65m.
| Cash flow per share | -0.4176 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.5643 |
|---|---|
| Tangible book value per share | 0.5643 |
More ▼
Balance sheet in USDView more
| Current ratio | 7.02 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
